Lori Hutson Email and Phone Number

Multiple indication launches for VENCLEXTA, a novel new oral BCL-2 inhibitor with Breakthrough Therapy Designation. Execute on actionable business plans, key sales competencies, collaborate with key cross functional partners to exceed sales goals and partnering with co-promotion partner AbbVie.Crew Team- collaborate with Regional Director to plan and be sounding board for colleaguesHOPS Team- communicate with district all data related informationProgram Coordinator- Work with MedForce, Detroit and Boston teams all all items dealing with programs

Launched PERJETA in neoadjuvant and metastatic breast cancer as well as KADCYLA in second line metastatic breast. HERCEPTIN market as the cornerstone for HER2 positive breast cancer. XELODA, a oral oncolytic for breast cancer. Collaborated with cross functional partners such as Biomarker testing team, and oncology clinical coordinator as well as practice navigators to meet customer needs. Exceeded business and sales goals.HER2 Region of the Year 2016PTP 192%- 2014HART Team- working with biomarker team on education with field salesTECH Champion for District- supported district on data (SLD, Javelin and Bounce Back data)

Launched oral agent ERIVEDGE, first in class hedge hog inhibitor marketed for basal cell carcinoma. Targets were dermatologists, oncologists and mohs surgeons. XELODA, an oral oncolytic for breast and colon cancers.

Promoted SANTYLl a topical treatment for diabetic ulcers. OASIS and ULTRA skin substitute devices

Promoted TAXOTERE, JEVTANA AND ELOXATIN (Breast, lung, prostate, head/neck and colon)Launched JEVTANA for metastatic prostate cancer. Exceeded projected sales.Eloxatin Brand Advisory CouncilEloxatin Field Based TrainerLINC- developed community outreach programsDistrict Computer ExpertThe American Cancer Society Board Member

Promoting the injectable LOVENOX for DVT treatment and prophylaxis in hospitals and medical practicesPromoted to Senior Sales ProfessionalRanked #1 in US prior to oncology promotionRing WinnerSales Representative of the DistrictTeam Work Award and Fast Start AwardGrew sales 17% in 8 months and reversed 3 therapeutic interchanges

Collaborating with functional teams to develop strategic plans and to insure successful block buster launches for ZYRTEC, TROVAN, CELEBREX, BEXTRA, RELPAX, AND ARICEPT. Many of these drugs required coordination of plans and execution with other companies such as Pharmacia, Eisai and UCB Pharma.

Effectively managed 60 staff members as well as 400 students. Consistently displayed ability to solve problems, improve processes and deliver results to help achieve the goals of the district.Recognized by State of Ohio for Inclusion ProgramDeveloped hundreds of Individualize Education Programs with measurable goals